INMD News and Press, InMode Ltd. From 02/23/23

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Investing in under-the-radar growth stocks can be a great way to gain exposure to companies that have the potential to outperform the market. By investing in these stocks, investors can capitalize on opportunities that may no...

InMode Ltd. ( NASDAQ: INMD ) dropped for the second straight session on Friday as the Israel-based MedTech company received the first Hold rating on Wall Street after Needham downgraded it from Buy, citing its Q4 2022 results. According to Seeking Alpha’s Wall Street ratings, I...

Sometimes the best opportunities are found in the laggards. Take medical technology (or medtech) stocks, for example. As a group, medtech stocks haven't performed well over the last year. However, their long-term potential should be great. Two underperforming medtech stocks especially stand o...

Image source: The Motley Fool. InMode (NASDAQ: INMD) Q4 2022 Earnings Call Feb 14, 2023 , 8:30 a.m. ET Operator Continue reading For further details see: InMode (INMD) Q4 2022 Earnings Call Transcript

InMode Ltd. (INMD) Q4 2022 Results Conference Call February 14, 2023 08:30 AM ET Company Participants Miri Segal - Investor Relations, MS-IR LLC Moshe Mizrahy - Chairman and Chief Executive Officer Dr. Michael Kreindel - Co-Founder and Chief Technology Officer Yair...

Following a four-day decline, the shares of Israel-based MedTech company InMode Ltd. ( NASDAQ: INMD ) gained on Tuesday as the company's Q4 2022 results exceeded Street forecasts despite underwhelming earnings guidance. The company focused on cosmetic procedure technologies reported $...

InMode press release ( NASDAQ: INMD ): Q4 Non-GAAP EPS of $0.78 beats by $0.09 . Revenue of $133.57M (+20.8% Y/Y) beats by $3.93M . InMode's proprietary surgical technology platforms engaged in minimally invasive and subdermal ablative treatments represented 83% of qua...

Summary InMode Ltd. is filling a treatment gap in the market with innovative, minimally invasive cosmetic procedure technologies. Most of InMode’s revenue comes from growing adoption of devices. Soon, though, sales will be primarily to update its installed unit base as growth ste...

Summary Although INMD's return on equity has decreased over the years, it still remains very attractive relative to most of the firms in the health care equipment industry. While the profit margin has contracted somewhat in 2022, due to the challenging macroeconomic environment, it has ...

Summary InMode Ltd. has 80%+ gross margins and 40%+ operating margins within a growing industry. The market is overestimating short-term worries that likely won't have a material effect on long-term cash flows. On both a relative basis and through a discounted cash flow, I estimate ...